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Objectives. This study sought o document postoperative com- 
plications attributable to nonthoracotomy defibrillation lead sys- 
tems in a large cohort. 
Background. The incidence of postoperative complications spe- 
cifically associated with nonthoracotomy defibrillation lead sys. 
terns is unknown. 
Methods. Postoperative l ad-related complications were evalu- 
ated in 170 patients with a nonthoracotomy defibrillation lead 
system who were followed up for a mean (-+SD) of 17 -+ 12 
months. Each system incorporated one or more intravascular 
leads. In 117 patients (69%), the system incorporated a subcuta- 
neous defibrillation patch. All implantations were performed in 
an operating room by cardiothoracic surgeons. Defibrillation 
thresholds were measured at implantation, before hospital dis- 
charge (mean 3 -+ 2 days) and at 4 to 18 weeks after implantation. 
Patients were evaluated every 2 to 3 months after implantation or 
as indicated by clinical exigency. 
Results. Twenty-seven patients (15.9%) were diagnosed with a 
lead-related complication that either extended the initial hospital 
period or led to a second hospital admission. Complications 
included endocardial lead or subcutaneous defibrillation patch 
dislodgment in eight patients (4.7%), which was diagnosed be- 
tween 2 and 345 days after implantation; endocardial or subcuta- 
neous patch lead fracture in six (3.5%), which was diagnosed 
between 53 and 600 days after implantation; subcutaneous patch 
mesh fracture in one, which was diagnosed at 150 days after 
implantation; subclavian vein thrombosis in three (1.8%), which 
was diagnosed at 2 to 50 days after implantation; and unaccept- 
ably elevated defibrillation threshold (within 5 J of maximal 
device output) in nine (5.3%), which was documented atone of the 
two postimplantation evaluations in eight patients or at the time 
of failure to terminate a spontaneous ventricular tachycardia in 
one. Seventeen of the 27 patients required reoperation for correc- 
tion of their complication. In addition, system infection requiring 
complete xplantation occurred in seven other patients (4.1%) at 
an interval from implantation ranging from 14 to 120 days. 
Conclusions. Postoperative complications related to a nontho- 
racotomy defibrillation lead system were common and frequently 
required reoperation for correction. The rate of system explanta- 
tion due to infection was also significant. Postoperative defibril- 
lation testing and vigilant outpatient follow-up evaluation are 
necessary to ensure normal ead function. 
(J Am Coil Cardiol 1995;26:776-86) 
Implantation of an implantable cardioverter-defibrillator uti-
lizing a nonthoracotomy lead system has resulted in a signifi- 
cant reduction in perioperative morbidity and mortality com- 
pared with implantation utilizing an epicardial lead system (1). 
Previous investigations (1,2) suggest that the incidence of 
arrhythmic death is low in patients with implantable defibril- 
lation systems that incorporate nonthoracotomy leads and is 
similar to that observed in patients with epicardial ead sys- 
tems. 
Postoperative complications associated with endocardial 
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pacing leads, such as dislodgment and fracture, are well 
described (3). Endocardial leads currently utilized for defibril- 
lation are more complex because they combine leads for both 
sensing and delivery of high energy shocks. In addition, 
nonthoracotomy defibrillation lead systems commonly incor- 
porate a subcutaneous patch. Little data are available concern- 
ing complications specifically related to these systems during 
the follow-up period (4). The purpose of the present study was 
to determine the incidence and type of postoperative compli- 
cations associated with nonthoracotomy defibrillation lead 
systems implanted in a large cohort of patients. 
Methods  
Patients. Between 1991 and 1994, 207 patients not requir- 
ing concurrent cardiothoracic surgery underwent attempted 
implantable cardioverter-defibrillator implantation utilizing a 
nonthoracotomy defibrillation lead system when such a system 
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Table 1. Defibrillation Lead Systems 
Medtronic CPI Ventritex 
Transvene Endotak TVL 
(n = 78) (n = 84) (n = 8) 
No. of leads* 2 1 2 
Diameter of distal lead'~ 10.5 12 10.5 
Diameter of proximal lead~: 8 - -  8 
Fixation mechanism§ Screw Tine Tine 
Sensing mode Bipolar Integrated Integrated 
*Separate leads comprising the endovascular portion of the system, tMaxi- 
mal diameter (F) of distal (right ventricular) lead (Medtronic model 6966; 
CPI models 0062, 0064, 0074; Ventritex model RV-1101). ~Maximal diameter 
(F) of proximal (superior vena cava/brachiocephalic vein) lead (Medtronic 
model 6963, Ventritex model SV-1101). §Refers to the distal lead. Bipolar = 
true bipolar; Integrated = utilization of a shock coil as the anode in the sense 
circuit. 
was available from the manufacturer. Of these patients, 170 
(82%) had successful nonthoracotomy defibrillation lead 
implantation. The remaining 37 patients had unacceptably 
high defibrillation thresholds with a nonthoracotomy de- 
fibrillation lead system and were referred for an epicardial 
system. These patients were not included in the remainder of 
the study. 
Of the 170 patients who underwent successful nonthora- 
cotomy defibrillation lead implantation (mean age 62 years, 
range 22 to 79), 138 (81%) were men, and chronic coronary 
artery disease with a previous myocardial infarction was 
present in 121 (71%). Previous cardiac surgery had been 
performed in 68 patients (40%). Mean left ventricular ejection 
fraction was 33 _+ 8% (range 9% to 65%). The initial clinical 
presentation was ventricular taehycardia n 63 patients (37%), 
cardiac arrest with ventricular fibrillation the first documented 
rhythm in 63 (37%) and syncope with inducible ventricular 
tachyarrhythmias n 44 (26%). 
Lead systems and devices. One of three different nontho- 
racotomy defibrillation lead systems was implanted (Table 1). 
The Medtronic Transvene system (Medtronic Inc.) was utilized 
in 78 patients. If necessary, a subcutaneous patch was incor- 
porated into the system (model 6999 [surface area 40 cm2]). 
The Transvene system was coupled to the Medtronic PCD 
device (model 7217B). The PCD incorporated bradycardia 
and antitachycardia p cing. In the pacing circuit, the distal 
tip of the right ventricular lead was cathodal and the lead 
designated as the shock cathode was anodal (5). Real-time 
electrograms were available from both the sense bipole and 
two of the defibrillation leads (including the cathode). Marker 
channels were available from the sensing bipole. Pacing and 
defibrillation circuit impedances were not available after im- 
plantation. 
The CPI Endotak system (Cardiac Pacemakers Inc.) was 
implanted in 84 patients. If necessary, a subcutaneous patch 
was incorporated into the system (model 0063 [surface area 
28 cm2]). In eight patients, a subcutaneous array lead (model 
0048) was implanted in place of the patch. Endotak systems 
were coupled to one of five devices: the Ventak 1550, 1555 and 
1600 (43 patients), the Ventak 1705 (18 patients) or the 
Ventritex Cadence (Ventritex Inc. [model V100]) (23 pa- 
tients). The Ventak 1500, 1555 and 1600 devices did not 
incorporate bradycardia or antitachycardia p cing. Defibrilla- 
tion circuit impedance was available only after a shock. The 
Ventak 1705 incorporated bradycardia nd antitachycardia 
pacing. Highly filtered real-time sense electrograms and 
marker channels were available. Defibrillation circuit imped- 
ance was available only after a shock. The Ventritex Cadence 
incorporated bradycardia nd antitachycardia pacing. Real- 
time electrograms from the sense circuit were available. The 
pacing impedance of the rate-sensing lead system could be 
measured uring interrogation, and the defibrillation circuit 
impedance was available only after a shock. 
The Ventritex TVL system was implanted in eight patients. 
TVL systems were coupled to the Cadence device (model 
Vll0). The Vll0 had the same features as the Ventritex 
Cadence V100 device. 
Of the 170 patients tudied, the implanted efibrillation 
lead configuration i cluded the endovascular lead (or leads) 
alone in 53 patients (31%). A single subcutaneous patch or 
array lead was included in the 117 remaining patients. 
Implantation procedure. The choice of a specific device 
and lead system was dictated primarily by availability. All 
implantation procedures were performed in the operating 
room by cardiovascular surgeons. In the absence of a eontra- 
indication, lead implantation was performed from the left side. 
The cephalic vein was cannulated by direct surgical cutdown 
whenever possible. Alternatively, the subclavian vein was can- 
nulated laterally by needle puncture. Under fluoroscopic guid- 
ance, the sensing cathode was placed at or near the right 
ventricular apex. The proximal defibrillating surface in a 
two-lead system (Transvene or TVL) was positioned in the 
superior vena cava or left brachiocephalic vein. The proximal 
defibrillating surface of the Endotak lead was usually in the 
superior vena cava, near its junction with the right atrium. 
When utilized, a subcutaneous patch electrode was centered 
on one of three sites on the thorax: the 7th intercostal space, 
anterior axillary line (apical); the 3rd intercostal space, mid- 
clavicular line (pectoral); the 7th intercostal space, midscapu- 
lar line (subscapular). In the latter position, the patch was 
actually submuscular, placed deep to the latissimus dorsi 
muscle and overlying the serratus anterior muscle. The subcu- 
taneous array lead was placed with its yoke just to the left of 
the sternum and the elements tunnelled subcutaneously par- 
allel the 5th to 7th intercostal margins, ending approximately 
at the anterior axillary line. 
An adequate R wave (>5 mV peak to peak) and pacing 
threshold (<1.5 V at 0.5-ms pulse width) were documented 
before proceeding to defibrillation testing. Intraoperative de- 
fibrillation threshold testing was performed through an exter- 
nal device (Medtronic ETCD, CPI ECD, or Ventritex 
HVSO2). Ventricular fibrillation (defined by typical appear- 
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ance on two surface ECG leads) was induced by either apid 
pacing or alternating current applied through the rate-sensing 
electrodes. After 10 s, a shock was delivered. The initial energy` 
for a given defibrillation lead configuration was 18 J 
(Medtronic), 20 J (CPI), and 650 V (Ventritex). After each 
successful defibrillation shock, the first shock energy was 
decremented by 2 to 3 J or 50 to 100 V, and the test was 
repeated. This process was repeated until there was a failure to 
defibrillate with the first shock. If the initial test energy, for a 
given lead configuration failed, the first shock energy was 
either incremented by 2- to 3-J steps until success, or the lead 
configuration was changed. The defibrillation threshold was 
defined as the lowest shock energy` that successfully terminated 
ventricular fibrillation. For a given defibrillation lead configu- 
ration, a criterion for generator implantation based on defi- 
brillation threshold was defined separately for each system: 
three of four successful ventricular fibrillation terminations al
-<18 J (Medtronic); three successful ventricular fibrillation 
terminations at <20 J (CPI); three successful ventricular 
fibrillation terminations at -<650 V (Ventritex). 
All pulse generators were placed in an abdominal pocket 
either subcutaneously or in the rectus heath posterior to the 
muscle. Leads were tunnelled subcutaneously to this pocket 
from their vascular or subcutaneous insertion sites. Most 
patients received prophylactic antibiotics (usually vancomycin 
with or without gentamicin) just before implantation and for 24 
to 48 h after the procedure. 
Follow-up evaluation. Postoperatively, all patients were 
evaluated inthe electrophysiology laboratory, on two occasions: 
before hospital discharge (3 +_ 2 days after implantation) and 
as an outpatient at 4 to 8 weeks (Medtronic), 8 to 12 weeks 
(CPI) or 14 to 18 weeks (Ventritex TVL system) after implan- 
tation. The laboratory, evaluation i cluded etermination f R 
wave amplitude, pacing threshold and ability of the system to 
sense and terminate ventricular termination or ventricular 
fibrillation, or both. The defibrillation threshold was deter- 
mined by starting at 2 to 3 J or 50 to 100 V above the 
defibrillation threshold measured at the previous test. For 
devices in which the first shock energy`' was not programmable. 
successful sensing and defibrillation were documented one or 
more times at the preprogrammed variables of the device. The 
defibrillation threshold was determined by the same "step-up/ 
step-down" method escribed previously. 
Outpatient follow-up included office visits every 2 to 3 
months. The standard evaluation i cluded interrogation ofthe 
device for arrhythmia events, determination f R wave ampli- 
tude and pacing thresholds and recording intracardiac electro- 
grams in devices where these features were available. 
Analytical methods. Continuous variables are presented as 
mean value _+ SD, unless otherwise stated. Incidence rates are 
expressed as a percent of the entire cohort, unless otherwise 
specified. The 95% confidence intervals (Cls) for the observed 
complication rates were calculated utilizing the normal approx- 
imation of the binomial distribution. 
Table 2. Endocardial Lead or Patch Dislodgment 
Lead Time 

























Access = approach utilized for dislodged lead; NA = not applicable; RV = 
right ventricular; SCL - subclavian vein puncture; SQ ~ subcutaneous; SVC = 
superior vena cava: Time = time of diagnosis after implantation. 
Resu l ts  
During a mean follow-up of 17 _+ 12 months, 27 patients 
(15.9%, 95% CI 10.4% to 21.4%) experienced complications 
directly associated with the nonthoracotomy defibrillation lead 
system that led to readmission tothe hospital or a prolongation 
of the initial hospital stay. Seventeen ofthese patients (10% of 
the entire cohort) underwent reoperation for the complication. 
Endocardial lead or patch dislodgment. Endocardial or 
subcutaneous defibrillation patch dislodgment occurred in 
eight patients (4.7%, 95% CI 1.5% to 7.9%) (Table 2). Five 
endocardial leads placed in the right ventricle were found to be 
dislodged at 2 to 47 days after implantation. In each case, the 
diagnosis was made by demonstrating an inability to pace 
through the lead at the maximal output of the device. Fluoro- 
scopic examination revealed that only one of the leads, all of 
which were Transvene l ads, had completely withdrawn from 
the right ventricle. Three of the leads had been implanted 
through the cephalic vein and two by direct subclavian vein 
puncture. Each patient who had a dislodged right ventricular 
lead underwent successful operative reimplantation of the 
same lead at the right ventricular apex. On the basis of this 
experience, we modified our method of endocardial lead 
anchoring. Leads had been anchored by a single suture sleeve 
to the prepectoralis fascia under the clavicle in the initial 
Transvene lead implantations. The modification was to loop 
the lead in this area and anchor each end of the loop separately 
with a suture sleeve. The goal of this loop was to prevent 
traction on the intravascular portion of the lead. Since this 
modification, in our last 44 Transvene implantations, there 
have been no lead dislodgments. 
In one patient, the superior vena cava lead was noted to 
have migrated proximally on routine chest radiograph 180 days 
after implantation. This lead had been placed through the 
cephalic vein and had also been anchored without a loop. 
Defibrillation testing revealed an adequate defibrillation 
threshold, and the lead was not repositioned. No further 
migration was documented during the subsequent 18-month 
follow-up. 
In two patients, folding of the subcutaneous patch on itself 
was noted. The first patient noted protrusion of the skin 
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Figure 1. Posteroanterior (left) and lateral (right) 
chest radiographs. Top, Several days after nonthora- 
cotomy defibrillation lead implantation, the subcuta- 
neous patch (arrows) has a regular contour and lies 
flush to the thoracic cage. Bottom, At 180 days after 
implantation, the subcutaneous patch (arrows) has 
folded longitudinally onitself such that a large portion 
of the electrical surface area is no longer in contact 
with the thoracic cage. 
overlying the patch beginning -180 days after implantation. 
The patch had initially been anchored only at its base, near the 
junction with the lead. Reoperation was performed because of 
concern that the patch would erode through the skin. At 
operation, the patch had folded away from the skin centrally 
but was structurally intact. It was flattened and reanchored at
each end, and an adequate defibrillation threshold was docu- 
mented. The second patient had patch folding noted on a 
routine follow-up chest radiograph 345 days after implantation 
(Fig. 1). The patch had been placed in the midaxillary line and 
secured to the underlying fascia at its base. The patient had 
reported no discomfort or skin changes before this time. After 
the radiographic observation, the patient underwent oninva- 
sive implantable cardioverter-defibrillator esting. Defibrilla- 
tion by the device could not be achieved with maximal energy 
delivery. At operation, the patch was folded but structurally 
intact. The fold was eliminated and the patch secured at both 
ends at the same site. Repeated testing demonstrated an 
adequate defibrillation threshold. 
Lead and patch mesh fractures. Fractures of the endocar- 
dial lead (five patients), subcutaneous patch lead (one patient) 
and subcutaneous patch mesh (one patient) were identified 
during follow-up (overall incidence 3.5%, 95% CI 0.7% to 
6.3%) (Table 3). Fractures of right ventricular endocardial 
leads were diagnosed at 53 to 600 days after implantation. The 
diagnosis was made in three of the five patients (each with an 
Endotak lead) after inappropriate shocks had been delivered. 
In each of these cases, oversensing was documented before 
lead replacement bymanipulation ofthe device in the abdom- 
Table 3. Lead and Patch Mesh Fractures 
Lead Time 
Type Access Manufacturer (days) 
Endotak Cephalic CPI 53 
RV SCL Medtronic 240 
Endotak SCL CPI 270 
Endotak SCL CPI 550 
Endotak Cephalic CPI 600 
SQ lead NA Medtronic 300 
SQ mesh NA CPI 150 
Format and abbreviations as in Table 2. 
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Figure 2. Top, Resected portion of an Endotak lead removed from a 
patient who had received spurious shocks beginning -500 days after 
implantation. Anarea of denuded insulation (arrow) was observed just 
distal to the lead yoke. This portion of the lead had been folded under 
the device in the abdominal pocket. Bottom, Closeup of the area of 
insulation breakdown. A long (-1.5 cm) area of denudation and 
exposure of the tip electrode conductor material was observed (ar- 
rows). 
inal pocket or by having the patient perform physical maneu- 
vers, such as adduction of the arm ipsilateral to the side of lead 
insertion. Implantation was through the cephalic vein in one 
patient and by direct subclavian vein puncture in two. Intra- 
operatively, before explantation, high frequency signals that 
could be sensed by the device were documented in each case, 
and pacing and shock impedances were normal. In one patient, 
the lead was explanted whole: in this lead no structural defect 
could be found by direct visualization or by the manufacturer. 
In the second patient, a 1.5-cm long area of denuded insulation 
was found just distal to the yoke of the lead, exposing the 
conductor of the tip electrode (Fig, 2). In the third patient. 
lead extraction was not attempted; no structural defect was 
visualized radiographically or on direct inspection of the 
portion of the lead in the abdominal pocket. The diagnosis of 
lead fracture was made in the other two patients during routine 
outpatient follow-up. In these patients, each of whom previ- 
ously had low pacing thresholds, no capture could be attained 
despite pacing at maximal output. The site of lead fracture was 
determined in each of these patients. In the first patient, the 
point of fracture was the portion of the lead between the 
clavicle and the first rib and could be easily seen radiograph- 
ically. This lead had been inserted by subclavian vein puncture. 
In the second patient, the point of fracture was near the lead 
pins. The silicone in this area had clearly eroded. Each of these 
Figure 3. Posteroanterior chest radiograph obtained at 150 days after 
nonthoracotomy defibrillation lead system implantation. The radio- 
opaque wire outlining the patch as a break, and the patch as subtle 
central curvature (arrows). This patch overlies the deltopectoral 
groove. 
five patients underwent reimplantation of a new lead of the 
same type with adequate sensing, and defibrillation thresholds 
were documented. 
One patient had a subcutaneous patch fracture. He had felt 
some discomfort at the patch site for several weeks. On 
physical examination, the skin overlying the patch was tented 
and thin. The chest radiograph revealed the radio-opaque 
border of the patch to have a fracture (Fig. 3). Operation was 
performed to prevent erosion. At operation, the patch was in 
uniform contact with the fascia overlying the deltopectoral 
groove. There was a linear mesh fracture along the center of 
the patch (Fig. 4). A new patch was implanted at the same site, 
and an adequate defibrillation threshold was documented. 
One patient had a fracture of a subcutaneous patch lead 
noted at routine follow-up 300 days after implantation. This 
patient had a Medtronic system with the patch designated as 
the pacing anode (5). The defect was diagnosed when pacing 
capture could not be achieved. Radiographs of the abdominal 
portion of the system revealed fracture of the patch lead just 
below the costal margin (Fig. 5). At operation, a transection of
the distal patch lead was demonstrated just below the costal 
margin (Fig. 6). Implantation ofa new patch was performed in
a similar site with adequate defibrillation threshold. 
Subclavian vein thrombosis. Three patients developed 
swelling of the upper extremity ipsilateral to the implanted 
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Figure 4. Closeup hotograph of the patch mesh from the patient whose 
radiograph is shown in Figure 3. The patch mesh ad a linear erosion 
(arrows) that had completely penetrated the mesh at most points. 
lead as a result of subclavian vein thrombosis, documented in 
each patient by noninvasive Doppler imaging (1.8%, CI 0% to 
3.8%). In the first two patients, this occurred before hospital 
Figure 5. Lateral radiograph centering on the diaphragm obtained at 
300 days after implantation f a Transvene system. The right ventric- 
ular lead is shown at the right ventricular pex (curved arrow). The 
right ventricular (solid arrow) and superior vena cava (open arrow) 
leads are shown coursing together subcutaneously with the subcutane- 
ous patch lead (multiple arrowheads). The proximal end of the 
transected patch lead is seen (star). 
(~ ii ~ ~i~ ' 
Figure 6. Subcutaneous patch removed from the patient whose radio- 
graph is shown in Figure 5. There had been a complete l ad transec- 
tion, including the insulation material. The ends of the transected 
insulation material have been reapposed for this photograph. Fraying 
of the conductor material isapparent (arrow). 
discharge after implantation. The approach was through the 
cephalic vein in one patient (Endotak) and direct subclavian 
puncture in the other (both leads of a Transvene system). In 
the third patient, swelling was first noted at 60 days after 
implantation. The venous approach in this patient was a direct 
subclavian puncture (Endotak). In each patient, venous throm- 
bosis was documented by Doppler studies. Systemic anticoag- 
ulation was instituted, and there was resolution of swelling 
without further sequelae in each patient. 
Unacceptable defibrillation threshold at follow-up. In 
eight patients an "unacceptable" increase in defibrillation 
threshold, defined as an increase to within 5 J of the maximal 
device output, was documented atone of the two postimplan- 
tation tests (Table 4). Each of these patients had had an 
adequate defibrillation threshold ocumented atimplantation. 
The increase was observed uring predischarge t sting in five 
patients and at the follow-up evaluation i three. In no patient 
was the antiarrhythmic drug regimen changed between defi- 
brillation threshold eterminations. There was no evidence of 
lead fracture or lead/patch migration associated with the 
increase in energy requirement for defibrillation in these 
patients. One additional patient received shocks for spontane- 
ously occurring uniform ventricular tachycardia at 150 days 
after implantation, which did not successfully terminate this 
rhythm (overall incidence 5.3%, CI 1.9% to 8.7%). He had had 
adequate defibrillation thresholds at each of the two routine 
postimplantation tests. Evaluation in the electrophysiology 
laboratory after readmission revealed an inability to defibril- 
late at maximal device output without apparent lead dislodg- 
ment or structural abnormality. 
In six of these patients, an adequate defibrillation threshold 
could be achieved without repeat surgical intervention (Table 
4). In three patients, a change in the antiarrhythmic drug 
regimen was sufficient. In the other three patients, the pathway 
for energy delivery was changed from sequential to simulta- 
neous (two patients) or from simultaneous tosequential (one 
patient), which was sufficient. Three patients underwent reop- 
eration for revision of the lead system. In one patient, an 
782 SCHWARTZMAN ETA[. .  JACC Vol. 26, No. 3 
NONTHORACOTOMY DEFIBRILLATION LEAD SYSTEM COMPLICATIONS September 1995:776-86 
Table 4. Unacceptable Defibrillation Threshold Increase During Follow-Up 
Manufacturer Device DFTimp* DFTf (days)- Intervention:~ DFTp§ 
Medtronic 7217B 1 ?, 34 {40) DC mexilitene 28 
Medtronic 7217B IS >34 (4) Amiodarone fl 28 
Medtronic 7217B I S 32 (40) DC amiodarone 24 
Medtronic 7217B 2(I >30 (4) D shock path I 24 
Medtronie 7217B 24 32 (2) D shock path 1 26 
Medtronic 7217B 1~ 34 (45) D shock path 2 26 
CPI 160tl 20 >30 {511) Add SQ patch 20 
Mcdtronic 7217B 18 32 (2) Epicard system 20 
Medtronic 7217B 18 >34 (150) Epicard system 28 
*Defibrillation threshold at implantation (Ji, tDefibrillation threshold measured at follow-up visit (number of days 
after implantation in parenthesis). $Alterations made in response to defibrillation threshold elevations: DC = 
discontinue: Amiodarone fl - decrease in dose from 400 to 200 rag/day; D shock path = PCD allows programmable 
designation of shock order in three-lead systems as simultaneous or sequential; D shock path 1 = sequential shock 
changed to simultaneous shock; D shock path 2 simultaneous shock changed to sequential shock; Add SQ patch = 
addition of a subcutaneous patch to a system: Epicard system - one to two epicardial patches required to obtain adequate 
defibrillation threshold. §Defibrillation threshold ocumented after intervention. 
acceptable defibrillation threshold was obtained with the ad- 
dition of a second subcutaneous defibrillation patch. In the 
other two patients, two epicardial patches were required. 
Postimplantation follow-up in this group is presently at a 
mean of 22 months (range 3 to 51)). Two patients have died. 
and one has been lost to follow-up. Neither of the deaths were 
arrhythmic in nature. Only one patient has thus far received 
device therapies for ventricular arrhythmias, including three 
successful episodes of antitachycardia p cing and a single low 
energy shock for uniform ventricular tachycardia. 
Infection requiring implantahle cardioverter-defibrillator 
system explantation. Seven other patients (4.1%, CI 1.1c'~ to 
7.1%) have required explantation of the device and lead 
system as a result of infection. The infection was identified 
within 1 month of implantation in five patients and within 3 
months of implantation i  the other two. The infecting organ- 
ism was Staphylococcus aureus in four patients, Staphylococcus 
epidermidis in two and Klebsiella pneumoniae in one. Each 
patient with a Staphylococcus sp. infection presented with fever 
and positive blood culture results. One of the patients present- 
ing within 1 month of implantation also had a sternal osteo- 
myelitis after coronaw revascularization surgery performed 
several weeks before nonthoracotomy defibrillation lead im- 
plantation. The patient who developed an infection 70 days 
after implantation had skin breakdown at the lead insertion 
site suture line caused by persistent scratching. At transesoph- 
ageal echocardiographic study, a large pedunculated vegeta- 
tion was shown to be adherent to the endocardial lead (Fig. 7). 
The other patient with late infection developed S. aureu.~ 
bacteremia from peripheral line sepsis during hospital admis- 
sion for congestive heart failure --90 days after implantation. 
After a course of intravenous antibiotic therapy, he redeve[- 
oped fever and had blood cultures growing the same organism. 
No patient had evidence of septic pulmonary, or systemic 
embolization. 
In six patients, explantation was accomplished without the 
need for thoracotomy. In the patient with lead vegetation, 
thoracotomy was performed because of concern for possible 
embolization. This patient underwent removal of the vegeta- 
tion by right atriotomy without cardiopulmonary b pass, after 
which the lead was removed. After a prolonged postexplanta- 
Figure 7. Yransesophageal echocardiographic images of the right 
ventricle obtained at end-systole (top) and end-diastole (bottom) in the 
patient who presented with an infected nonthoracotomy defibrillation 
lead system. A large mobile vegetation (m) was attached to the lead 
(L) as it passed through the tricupsid valve (tv). This vegetation was 
shown to be an organized thrombus without bacteria seen pathologi- 
cally, but this patient had been receiving a long course of high dose 
intravenous antibiotic therapy by the date of operation. RA = right 
atrium; RV = right ventricle. 
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tion course of antibiotics therapy, six patients have undergone 
successful reimplantation of a new nonthoracotomy defibrilla- 
tion lead system. No patient has had recurrence of lead 
infection at a mean follow-up of 10 months (range 2 to 24). 
One patient refused reimplantation, and amiodarone was 
started. 
Discussion 
The major finding of the present study was the high inci- 
dence of complications specifically associated with the lead 
system in patients who underwent successful implantation of 
an implantable cardioverter-defibrillator using a nonthora- 
cotomy defibrillation lead system. Endocardial lead dislodg- 
ment occurred early after implantation. It was observed mainly 
in association with the Transvene right ventricular lead and 
was probably due to inadequate anchoring technique. Simi- 
larly, subclavian vein thrombosis occurred early after implan- 
tation. Endocardial and subcutaneous defibrillation patch lead 
fracture or malfunction occurred later after implantation, as 
did subcutaneous patch dislodgment. Defibrillation threshold 
elevation to unacceptable l vels was typically noted at either 
predischarge or early followup testing. Infection requiring 
explantation was observed both early and late after explanta- 
tion. To our knowledge, none of the 170 patients in this cohort 
has died as a result of nonthoracotomy defibrillation lead 
system dysfunction. 
Lead dislodgment. Dislodgment of modern right ventricu- 
lar endocardial pacing leads is uncommon, with an incidence of 
<2% in experienced centers (3). Stambler et al. (6) reported a
2% incidence of standard endocardial pacing lead dislodgment 
in 281 patients who had undergone lead implantation in 
association with the Telectronics Guardian ATP 4210 device. 
Frequent dislodgment of the endocardial shock-delivering lead 
in the early implantable cardioverter-defibrillator experience 
resulted in the preferential use of a totally epicardial shocking 
lead system (7,8). Epicardial systems have had a low rate of 
dislodgment. Grimm et al. (8) reported a 1% incidence of 
epicardial lead dislodgment among 191 consecutive patients. 
Recent experience with endocardial defibrillation leads has 
also shown dislodgment to be a clinically serious problem. 
Bardy et al. (9) reported lead dislodgment requiring surgical 
revision in 8 of 80 patients who underwent a Yransvene system 
implantation. All were diagnosed within 6 weeks of implanta- 
tion, the majority within the first week. Of these eight dislodg- 
ments, three were right ventricular leads, and the remaining 
five were defibrillation coils that had been placed in the 
coronary sinus. A more recent report by Bardy et al. (10) of 
148 Transvene system implantations described 11 endocardial 
lead dislodgments (7.4%). These investigators described (9,10) 
a marked reduction in the occurrence of lead dislodgment in
their more recent implant recipients, which they ascribed to 
modifications in lead anchoring technique and operator expe- 
rience. Similarly, Sra et al. (11) reported a lead dislodgment 
rate of 5% among 170 patients who underwent nonthora- 
cotomy defibrillation lead implantation. The occurrence of 
dislodgment was limited to the 115 patients who underwent 
implantation of a Transvene system (7% incidence). In five 
patients, the dislodgment was diagnosed within 24 h of implan- 
tation. The dislodged lead was a coil in the coronary sinus (five 
patients) or superior vena cava (three patients). Sra et al. (11) 
reported that the incidence of dislodgment had since been 
significantly attenuated by improved anchoring techniques and 
extremity immobilization in the early postoperative period. 
The rate of dislodgment ofthe Endotak lead appears to be very 
low. Hauser et al. (12) did not observe a single episode of 
dislodgment in 414 patients enrolled in a multicenter Endotak 
transvenous lead clinical trial. No data have been published yet 
with regard to follow-up after TVL implantation. In the 
present study, the diagnosis of endocardial lead dislodgment 
was limited to the Transvene system, similar to the findings of 
Sra et al. (11). However, unlike that study (11), five of our six 
Transvene dislodgments were of the right ventricular lead. This 
problem was most likely related to technique because it seems 
to have resolved with lead anchoring techniques designed to 
decrease the tension on the intravascular portion of the lead. 
In this regard, our initial experience with transvenous defibril- 
lation was predominantly with the Transvene system; our 
Endotak implantation technique may have benefited from this 
early experience. For example, most Endotak implantations 
have included the lead anchoring modifications previously 
described. Also, the different ICD devices have varied capa- 
bilities to identify the presence of lead dislodgment. For 
example, a significant portion of our Endotak implantations 
were in association with Ventak 1550, 1555 or 1600 devices, 
none of which have pacing capability. The diagnostic lue in all 
but one of the Transvene lead dislodgments was failure to 
demonstrate ventricular capture at maximal output. It is 
possible that early dislodgments of the Endotak lead, which 
were radiographically inapparent but would have been diag- 
nosed because of a marked elevation of pacing threshold, were 
missed in our patient cohort. However, the ability to sense and 
terminate ventricular fibrillation was confirmed in all patients 
with the Endotak lead system coupled with the Ventak devices. 
This finding would suggest hat lead dislodgment, if present, 
did not result in clinically significant sensing problems. 
Albeit rare, the subcutaneous defibrillation patch may also 
be subject o dislodgment. Jones et al. (10) described one 
episode of pectoral patch dislodgment that required surgical 
revision. In two patients in the present report, the patch 
remained in the same area but folded on itself, causing 
overlying skin thinning or inadequate defibrillation threshold. 
In each case, the patch had been sutured only at one end. 
Lead and patch fracture. Fracture of standard ventricular 
endocardial pacing leads used for sensing/pacing in association 
with implantable cardioverter-defibrillators utilizing epicardial 
shocking leads has been uncommon. Stambler et al. (6) 
reported a 1% incidence among various commercially avail- 
able leads used in patients followed up for a mean of -1 year 
with the Telectronics device. Thomas et al. (13) reported an 
incidence of fracture of 0.6% and insulation break of 0.3% in 
3,610 patients with the AICD implanted between 1982 and 
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1988. Fracture of endocardial pacing leads is frequently asso- 
ciated with anatomic onstraint at points of stress, such as 
between the clavicle and first rib in association with implanta- 
tion using a standard subclavian approach, or near the point of 
insertion of the lead pins into the device header (14). 
Fracture of epicardial sensing and defibrillation leads has 
been uncommon. For example, during a mean follow-up of 
31 _+ 12 months, Grimm et al. (8) reported an incidence of lead 
fracture of only 3.7% among 191 patients with epicardial lead 
systems. In contrast, early experience with early endocardial 
defibrillation leads showed fracture to be common. For exam- 
ple, Tullo et al. (15) reported three fractures in nine implan- 
tations of the Endotak 50 series lead at a mean follow-up of - 1 
year. Experience with currently available leads suggests that 
the incidence is lower. Jones et al. (10) reported three endo- 
cardial lead fractures in 148 Transvene implantations, one 
involving aright ventricular lead and two a coronary sinus lead. 
The fracture was located between the clavicle and first rib at 
the subclavian vein insertion point. Renzulli et al. (16) re- 
ported a similar occurrence in a patient with the Endotak lead. 
In the present study, five endocardial lead fractures occurred. 
an incidence of 2.9%. Two occurrences were attributable to 
stress points (calvicle-first rib and pin-device header junc- 
tions). In the third case, erosion of the lead insulation material 
could have been due to contact between the implantable 
cardioverter-defibrillator can and the lead, which had been 
folded under the can in the abdominal pocket (Fig. 2). In the 
other two cases, both Endotak leads, no definite mechanism 
could be established because the site of the lead interruption 
could not be identified. The inability to explant dysfunctional 
defibrillation leads, such as chronically implanted tined leads. 
will hinder the elucidation of mechanisms of lead dysfunction 
(17). 
The single-patch lead fracture seen in our cohort occurred 
near the left costal margin. Jones et al. (10) and Tullo et al. 
(15) reported on patients with fractures of patch leads in a 
similar area. One of these patients (10) died suddenly with 
documented failure to terminate ventricular fibrillation. The 
costal margin appears to be a point of stress on the leads as 
they course subcutaneously over the rib cage into the abdo- 
men. The presentation f our patient is also illustrative of one 
of the limitations placed on follow-up evaluation of current 
nonthoracotomy defibrillation lead systems. This patient had a 
PCD device, utilizing a Transvene lead system that included a 
subcutaneous patch. In the lead configuration that achieved an 
optimal defibrillation threshold intraoperatively, the patch was 
designated as cathodal. Pacing by the PCD thus utilized the 
patch as anodal (5). Had the patch not been part of the pacing 
configuration, there would have been no indication that the 
fracture had occurred. Fracture of the lead was only subtly 
apparent in overpenetrated ra iographs of the abdomen (Fig. 
5). 
To our knowledge, subcutaneous patch mesh fracture has 
not been reported previously. Mittleman et al. (18) reported 
Silastic erosion and mesh fraying of an epieardial patch that 
had become folded over several months. In our patient, mesh 
fracture may have been attributable topositioning the patch in 
the deltopectoral groove. This position probably subjected the 
patch to a repeated hinge-like stress during upper extremity 
motion. 
The frequent occurrence of lead fracture in the present 
study raises questions regarding utilization of nonthoracotomy 
defibrillation lead systems in very physically active patients. 
Although our cohort is too small to draw any conclusions about 
the relation of lead component fracture and level of physical 
activity, experience with pacemaker leads has suggested such a 
correlation (13). Follow-up of young patients with implantable 
cardioverter-defibrillator utilizing nonthoracotomy defibrilla- 
tion lead systems i preliminary at present. An excessive rate of 
lead complications has not yet been encountered (19). 
Subclavian vein thrombosis. Subclavian vein thrombosis 
a rare complication of standard bradycardia pacing lead im- 
plantation (3). The incidence was higher with the use of larger 
vascular spring leads used in earlier defibrillation lead systems 
(7,20). Bardy et al. (9) described subclavian vein thrombosis n 
2 of 80 patients with the Transvene system. In the present 
study, it occurred with placement of the leads through either 
the cephalic or the subclavian vein. In each case, full resolution 
of swelling was seen over several weeks after institution of 
anticoagulation. 
Unacceptable defibrillation threshold in follow-up. In the 
present study, nine patients (5%) had an unacceptably high 
defibrillation threshold at follow-up device testing early after 
implantation. A significant increase in mean defibrillation 
threshold early and at 6 months after implantation has been 
documented after nonthoracotomy defibrillation lead implan- 
tation (21-23). Fortunately, in most of our patients, alterations 
in antiarrhythmic drug regimen or sequence of shock delivery 
resulted in an implantable cardioverter-defibrillator system 
with an adequate defibrillation safety margin. 
Infection requiring implantable cardioverter-defibrillator 
system explantation. Infection requiring explantation of uti- 
lizing epicardial lead systems has ranged from 2% to 7% in 
experienced centers (24). The majority of cases appear to be 
mediated by intraoperative contamination a d are caused by 
S. aureus (8). Infection requiring explantation of endocardial 
pacing leads is unusual in single- or dual-chamber pacing 
systems (3). Blakeman et al. (25) reported on a single patient 
with infection requiring system explantation during follow-up 
of 85 consecutive patients with nonthoracotomy defibrillation 
lead systems. Hauser et al. (12) reported a 1.3% incidence of 
infection requiring explantation during follow-up of 414 pa- 
tients with an Endotak system. In the multicenter xperience 
with the Medtronic PCD (1), the incidence of infection requir- 
ing explantation was 3.6% among patients with a Transvene 
system. This incidence of infection was significantly higher 
than the incidence of 1.6% in the patients who had epicardial 
systems. The 4.0% incidence of infection in the present study 
is consistent with these findings. In our cohort, early infection 
was due to S. aureus in three of five patients. One of the late 
presentations with infection was apparently due to seeding of 
the implantab/e cardioverter-defibrillator system during bacte- 
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remia. Although infection is hardly specific for implantable 
cardioverter-defibrillator systems that incorporate nonepicar- 
dial leads, we thought it important o include infection as a 
possible complication of nonthoracotomy defibrillation lead 
systems. Of note, bacteremia is uncommonly observed in 
association with implantable cardioverter-defibrillator system 
infections associated with epicardial defibrillation lead sys- 
tems. Furthermore, it appears that seeding of the endovascular 
lead system from other sources of infection such as infected 
phlebitis may be more common with nonthoracotomy defibril- 
lation lead systems than with epicardial systems. After removal 
of the implantable cardioverter-defibrillator system and a 
prolonged course of intravenous antibiotic therapy, we were 
able to successfully implant another nonthoracotomy defibril- 
lation lead system in each of six patients. None of these 
patients has returned with recurrent system infection to date. 
Summary. With a mean follow-up of only 17 months, we 
report a 16% incidence of complications associated with 
nonthoracotomy defibrillation lead systems that extended the 
initial hospital period or led to repeat hospital admission. 
Operative revision to correct he problem was necessary in the 
majority of these patients. On the basis of our experience with 
nonthoracotomy defibrillation lead systems, we have modified 
our practice to attempt o eliminate or reduce lead-related 
complications: 1) We now perform meticulous anchoring of 
endocardial leads to minimize tension on the intravascular 
portion. Similarly, subcutaneous patches are anchored at mul- 
tiple points. 2) Venous access is achieved through cephalic or 
lateral subclavian approaches (26). Points of mechanical stress 
are considered for other components of the lead system. For 
example, the subcutaneous patch implanted in the pectoral 
position is kept away from the deltopectoral groove. 3) Defi- 
brillation threshold testing is performed before hospital dis- 
charge after implantation and again at -2  months. Biphasic 
shock waveforms are used whenever possible (27). The addi- 
tion of any new antiarrhythmic drug is accompanied by re- 
peated device testing to document defibrillation efficacy. 4) 
Vigilant outpatient follow-up is maintained to ensure lead 
integrity and proper function and includes regular outpatient 
visits for history, physical examination and device interroga- 
tion. High quality radiographic images of all implantable 
cardioverter-defibrillator system components are obtained at 3 
months after implantation, then every 6 months thereafter. 
Lead system dysfunction is considered if a history of sudden 
change in the pattern of implantable cardioverter-defibrillator 
therapy occurs and would include frequent implantable 
cardioverter-defibrillator therapies occurring in the absence of 
symptoms, as well as multiple sequential discharges ina patient 
with a previously acceptable defibrillation threshold. A method 
for assessing defibrillation circuit integrity without necessitat- 
ing shock delivery is highly desirable and must be incorporated 
into future implantable cardioverter-defibrillator s),stems. 
We thank Kimberly L. Quaranta RN, BSN for essential assistance in the 
preparation of this report. 
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